Merck, the drugmaker facing 900 lawsuits over claims that its osteoporosis drug Fosamax causes the death of jawbone tissue, goes to trial tomorrow in a case that may affect all the others.
The trial in New York of the first case of the group, filed by Shirley Boles, 71, will be one of three so-called bellwether cases that may point the way to out-of-court settlements.
“In mass litigation, all eyes are on the first trial, not only because it shows the strategy of each side, but also because it’s the first information about how jurors respond to the evidence,” said Howard Erichson, a law professor at Fordham University in New York and an expert on civil procedure.
More
2 comments:
900 lawsuits... that quite a bit of dough re me
It's more than 1,000 actually. The first trial just began and here is more information on it and the dangers of Fosamax: http://www.newsinferno.com/archives/11711#more-11711
Post a Comment